EPEdward Price

Edward Price

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Edward Price has a total of 49 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Developing Predictive Models by Sharing Predictions – An Investigation of a Federated Learning Approach for ADMET Predictions

    by Rajarshi Guha, Wenyi Wang, Edward Price, Barun Bhhatarai, Majdi Hassan, Anthony DiFranzo, Christopher Keefer, Nathaniel Woody, Fabio Broccatelli, Susanne Winiwarter, et al.

    Machine learning models for ADMET prediction benefit from large, diverse data sets, yet such data are typically siloed across organizations. Federated learning (FL) enables collaborative modeling while preserving data privacy. Here, we investigate a student–teacher model (STM) framework in which organizations train internal models on proprietary data and share predictions on a public data set to generate pseudolabels for a centralized student model. As a proof of concept, 11 pharmaceutical companies contributed predictions for rat steady-state volume of distribution, yielding a pseudolabeled data set of ∼133,000 compounds. The resulting student model achieved performance comparable to individual teacher models on an external test set (RMSE ≈ 0.51 vs 0.47–0.61). Compared with FL approaches such as MELLODY and Effiris, STM offers a simpler workflow that avoids direct data sharing or iterative collaboration, providing a practical and scalable framework for secure cross-company model development.


  • Early-stage prediction of human intestinal metabolism from in vitro liver microsomal clearance

    by Ryan Arey, Edward Price, Louis Lin, David Stresser, Ryota Kikuchi

  • Explainable Machine Learning for ETR and Drug Chameleonicity

    by Edward Price, Matthieu Dagommer, Mattson Thieme, Richard Hong, J. Cory Kalvass, Stella Doktor, Alexey Rivkin, Yue-Ting Wang, Philip Cox, Abhishek Pandey, et al.

    Explainable machine learning that identifies molecular “hot spots” for chameleonicity can guide rapid chemical design for oral absorption of beyond-rule-of-five (bRo5) drugs. Traditional in silico methods rely on computationally intensive 3D physics-based modeling or classical descriptors that do not fully explain bRo5 drug behavior. To address this, we introduced the EPSA-to-TPSA ratio (ETR) as a high-throughput measure of polarity reduction, generating data for thousands of macrocycles, PROTACs, and other bRo5s. Using this data set, we developed an explainable deep learning model to predict EPSA and locate polarity-reducing “hot spots” that influence chameleonicity. This first-of-its-kind interpretable model in the bRo5 3D domain guides chemical modifications before synthesis, helping chemists optimize physicochemical properties and design complex bRo5 drugs with improved oral bioavailability. Model insights validated by molecular dynamics enable robust, high-throughput predictions of bRo5 chameleonic behavior, building on Lipinski descriptors to establish new frameworks for complex drug design.


  • Open Access

    AURA: Accelerating drug discovery with accuracy, utility, and rank-order assessment for data-driven decision making

    by Edward Price, Virginia Saulnier, John Cory Kalvass, Stella Doktor, Manuel Weinheimer, Majdi Hassan, Spencer Scholz, Marjoleen Nijsen, Gary Jenkins


  • High-Throughput SFC-MS/MS Method to Measure EPSA and Predict Human Permeability

    by Yue-Ting Wang, Edward Price, Mei Feng, Jason Hulen, Stella Doktor, David M. Stresser, Estelle M. Maes, Qin C. Ji, Gary J. Jenkins

    Permeability is a key factor driving the absorption of orally administered drugs. In early discovery, the efficient evaluation of permeability, particularly for compounds violating Lipinski's Rule of 5, remains challenging. Addressing this, we established a high-throughput method to measure the experimental polar surface area (HT-EPSA) as an in vitro surrogate to measure permeability. Compared to earlier methods, HT-EPSA significantly reduces data acquisition time with enhanced sensitivity, selectivity, and data quality. In the effort of translating EPSA to human in vitro and in vivo passive permeability, we demonstrated the application of EPSA for predicting Caco-2 cell and human intestinal permeability, showing improvements over topological polar surface area and the parallel artificial membrane permeability assay for rank-ordering permeability in a proteolysis targeting chimera case study. The HT-EPSA method is expected to be highly beneficial in guiding early stage compound rank-ordering, faster decision-making, and in predicting in vitro and/or in vivo human intestinal permeability.


  • Open Access

    Conquering the beyond Rule of Five Space with an Optimized High-Throughput Caco-2 Assay to Close Gaps in Absorption Prediction

    by Patricia Muschong, Khader Awwad, Edward Price, Mario Mezler, Manuel Weinheimer

    Current drug development tends towards complex chemical molecules, referred to as “beyond rule of five” (bRo5) compounds, which often exhibit challenging physicochemical properties. Measuring Caco-2 permeability of those compounds is difficult due to technical limitations, including poor recovery and detection sensitivity. We implemented a novel assay, with optimized incubation and analytics, to measure permeability close to equilibrium. In this setup an appropriate characterization of permeability for bRo5 compounds is achievable. This equilibrated Caco-2 assay was verified with respect to data validity, compound recovery, and in vitro to in vivo correlation for human absorption. Compared to a standard assay, it demonstrated comparable performance in predicting the human fraction absorbed (fa) for reference compounds. The equilibrated assay also successfully characterized the permeability of more than 90% of the compounds analyzed, the majority of which were bRo5 (68%). These compounds could not be measured using the standard assay. Permeability and efflux ratio (ER) were highly predictive for in vivo absorption for a large set of internal bRo5 compounds. Reference cut-offs enabled the correct classification of high, moderate, and low absorption. This optimized equilibrated Caco-2 assay closes the gap for a high-throughput cellular permeability method in the bRo5 chemical space.


  • Top Cited Papers

    Beyond Rule of Five and PROTACs in Modern Drug Discovery: Polarity Reducers, Chameleonicity, and the Evolving Physicochemical Landscape

    by Edward Price, Manuel Weinheimer, Alexey Rivkin, Gary Jenkins, Marjoleen Nijsen, Philip B. Cox, David DeGoey

    Developing orally bioavailable drugs demands an understanding of absorption in early drug development. Traditional methods and physicochemical properties optimize absorption for rule of five (Ro5) compounds; beyond rule of five (bRo5) drugs necessitate advanced tools like the experimental measure of exposed polarity (EPSA) and the AbbVie multiparametric score (AB-MPS). Analyzing AB-MPS and EPSA against ∼1000 compounds with human absorption data and ∼10,000 AbbVie tool compounds (∼1000 proteolysis targeting chimeras or PROTACs, ∼7000 Ro5s, and ∼2000 bRo5s) revealed new patterns of physicochemical trends. We introduced a high-throughput "polarity reduction" descriptor: ETR, the EPSA-to-topological polar surface area (TPSA) ratio, highlights unique bRo5 and PROTAC subsets for specialized drug design strategies for effective absorption. Our methods and guidelines refine drug design by providing innovative in vitro approaches, enhancing physicochemical property optimization, and enabling accurate predictions of intestinal absorption in the complex bRo5 domain.


  • Global Analysis of Models for Predicting Human Absorption: QSAR, In Vitro, and Preclinical Models

    by Edward Price, J. Cory Kalvass, David DeGoey, Balakrishna Hosmane, Stella Doktor, Kelly Desino

    Models intended to predict intestinal absorption are an essential part of the drug development process. Although many models exist for capturing intestinal absorption, many questions still exist around the applicability of these models to drug types like “beyond rule of 5” (bRo5) and low absorption compounds. This presents a challenge as current models have not been rigorously tested to understand intestinal absorption. Here, we assembled a large, structurally diverse dataset of ∼1000 compounds with known in vitro, preclinical, and human permeability and/or absorption data. In silico (quantitative structure–activity relationship), in vitro (Caco-2), and in vivo (rat) models were statistically evaluated for predictive performance against this human intestinal absorption dataset. We expect this evaluation to serve as a resource for DMPK scientists and medicinal/computational chemists to increase their understanding of permeability and absorption model utility and applications for academia and industry.


  • Open Access

    Animal simulations facilitate smart drug design through prediction of nanomaterial transport to individual tissue cells

    by Edward Price, Andre J. Gesquiere

    A state-of-the-art in vitro to in silico animal body simulation successfully predicts biodistribution with cellular resolution.